Open an account

Transcat

TRNS · NASDAQ

$81.71+$1.03 (+1.28%)TodayMarket closed ·
Prev close $80.68

About TRNS

Transcat, Inc. engages in the provision of calibration and laboratory instrument services. The company is headquartered in Rochester, New York and currently employs 1,245 full-time employees. The company is focused on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceuticals, biotechnology, medical devices, as well as aerospace and defense, and energy and utilities. The company provides periodic on-site services, mobile calibration services, pickup and delivery, and in-house services at Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Its segments include Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services. The Distribution segment sells and rents national and proprietary branded instruments to customers globally.

Employees
1,245
Headquarters
Rochester, New York
Listed
Jul 5, 1965
Sector
Industrials
Industry
Trading Companies & Distributors
Website
transcat.com

TRNS key statistics

Market cap
755.15M
Price-earnings ratio
224.11
Dividend yield
—
Average volume
119.28K
Volume
177.32K
Open price
$80.61
High today
$82.22
Low today
$79.85
52 Week high
$100.00
52 Week low
$50.23

Transcat (TRNS) at a glance

Transcat (TRNS) last traded at $81.71, with a market cap of 755.15M and a price-to-earnings ratio of 224.11.

Today the stock has traded between $79.85 and $82.22. The current price is 2.3% above the day's low and 0.6% below its high.

Volume so far is 177.32K shares, above the average of 119.28K shares a day.

Over the past year Transcat has ranged from $50.23 to $100.00, and now sits 63% of the way up that range.

Transcat met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.51 per share against an estimate of $0.3851.

TRNS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 28.5% on average.

  1. Q4 FY24: reported $0.77 per share against an estimate of $0.5386
  2. Q1 FY25: reported $0.48 per share against an estimate of $0.3638
  3. Q2 FY25: reported $0.35 per share against an estimate of $0.4726
  4. Q3 FY25: reported $0.25 per share against an estimate of $0.329
  5. Q4 FY25: reported $0.39 per share against an estimate of $0.38
  6. Q1 FY26: reported $0.56 per share against an estimate of $0.5687
  7. Q1 FY27: reported $0.51 per share against an estimate of $0.3851
  8. Q2 FY26: reported $0.51 per share against an estimate of $0.3851

TRNS news

  • Press releaseBusiness Wire

    Transcat to Host Second Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, November 3, 2026 at 4:30 p.m. Eastern Time

  • Press releaseBusiness Wire

    Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical

  • Press releaseBusiness Wire

    Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September

  • Press releaseBusiness Wire

    Transcat Reports Strong Fiscal First Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Service Gross Margin Expansion

  • Press releaseBusiness Wire

    Transcat to Host First Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, August 4, 2026 at 4:30 p.m. Eastern Time

  • Press releaseBusiness Wire

    Transcat Announces Appointment of Roy Simmons as Chief Strategy and Corporate Development Officer

  • Full Transcript: Transcat Q4 2026 Earnings Call

  • Press releaseBusiness Wire

    Transcat Reports Strong Fiscal Fourth Quarter 2026 Financial Results with Continued High Single-Digit Service Organic Revenue* Growth

Similar companies

Companies in the same industry as Transcat

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.